NASDAQ:ORKA • US6876041087
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ORUKA THERAPEUTICS INC (ORKA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-04-28 | UBS | Maintains | Buy -> Buy |
| 2026-04-28 | Barclays | Maintains | Overweight -> Overweight |
| 2026-04-27 | BTIG | Maintains | Buy -> Buy |
| 2026-04-15 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-04-13 | Guggenheim | Reiterate | Buy -> Buy |
| 2026-04-13 | BTIG | Maintains | Buy -> Buy |
| 2026-04-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-04-09 | Guggenheim | Reiterate | Buy -> Buy |
| 2026-04-07 | Barclays | Maintains | Overweight -> Overweight |
| 2026-04-06 | Guggenheim | Maintains | Buy -> Buy |
| 2026-04-06 | UBS | Maintains | Buy -> Buy |
| 2026-03-16 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-03-13 | Guggenheim | Reiterate | Buy -> Buy |
| 2026-03-13 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-13 | Stifel | Maintains | Buy -> Buy |
| 2026-03-13 | Barclays | Maintains | Overweight -> Overweight |
| 2026-03-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-01-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-12 | BTIG | Maintains | Buy -> Buy |
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-12-18 | Piper Sandler | Initiate | Overweight |
| 2025-11-13 | BTIG | Maintains | Buy -> Buy |
| 2025-11-13 | Jefferies | Initiate | Buy |
| 2025-10-27 | Guggenheim | Initiate | Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 814.94% | N/A 262.55% | N/A 87.34% | ||||||||||||
| EBITDA YoY % growth | -11.44M | -16.59M -45.02% | -18.68M -12.60% | -8.1M 56.64% | -5.79M 28.52% | -9.76M -68.57% | -19.319M -97.94% | -10.576M 45.26% | -7.281M 31.16% | -88.096M -1,109.94% | -121.968M -38.45% | N/A -22.44% | N/A -7.44% | N/A -18.49% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.46M | -16.61M -44.94% | -18.71M -12.64% | -8.12M 56.60% | -5.81M 28.45% | -9.77M -68.16% | -19.335M -97.90% | -10.596M 45.20% | -7.296M 31.14% | -88.123M -1,107.83% | -122.051M -38.50% | N/A -20.87% | N/A -19.49% | N/A -29.49% | N/A -46.42% | N/A -23.72% | N/A 30.92% | N/A 244.74% | N/A 199.20% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -120.96 71.85% | -54.36 55.06% | N/A | N/A | N/A | N/A | N/A | -1.86 46.51% | N/A -29.10% | N/A -16.33% | N/A -21.41% | N/A -18.38% | N/A -12.45% | N/A 45.28% | N/A 327.09% | N/A 148.65% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.56 -40.04% | -0.59 -27.85% | -0.63 -14.58% | -0.64 -42.19% | -0.65 -16.54% | -0.68 -16.38% | -0.73 -15.21% | -0.78 -21.68% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -37.347M -48.88% | -39.186M -37.84% | -42.104M -23.45% | -43.943M -27.63% | -42.331M -13.35% | -43.883M -11.99% | -47.424M -12.64% | -53.827M -22.49% |
All data in USD
20 analysts have analysed ORKA and the average price target is 91.96 USD. This implies a price increase of 46.94% is expected in the next year compared to the current price of 62.58.
ORUKA THERAPEUTICS INC (ORKA) will report earnings on 2026-05-20.
The consensus EPS estimate for the next earnings of ORUKA THERAPEUTICS INC (ORKA) is -0.56 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering ORUKA THERAPEUTICS INC (ORKA) is 20.